STAT+: 6 things to know before the readout of Rafael Pharma’s pancreatic cancer drug study
Pancreatic cancer is hard to detect early and notoriously resistant to treatment, making it the deadliest type of major cancer. Rafael Pharmaceuticals, a small drug maker backed by a telecom billionaire, hopes to deliver better news for patients and investors with the readout of a large clinical trial within the next two months.
It’s an inordinately risky challenge for Rafael, but with a giant payoff if successful. Here are six things to know about the company and its drug, devimistat, before Phase 3 pancreatic cancer study results are announced.
